Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective

American Journal of Gastroenterology

Volumn 98, Issue 3, 2003, Pages 600-607

  Longstreth, George F ^a   Wilson, Alisa ^a   Knight, Kevin ^a   Wong, John ^a   Chiou, Chiun Fang ^a   Barghout, Victoria ^a   Frech, Feride ^a   Ofman, Joshua J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; DIPHENOXYLATE; LAXATIVE; LOPERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HUMAN; IRRITABLE COLON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOLOGY; SEX; SIGMOIDOSCOPY; SYMPTOMATOLOGY;

EID: 0037344032     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07296.x     Document Type: Article

References (31)

1. Thompson WG, Longstreth GF, Drossman DA, et al. Rome II: The functional gastrointestinal disorders, 2nd ed. McLean, VA: Degnon Associates, 2000.
2. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001;344:1846-50.
3. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100:998-1005.
4. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000;17:331-8.
5. Longstreth GF. Irritable bowel syndrome: A multibillion-dollar problem. Gastroenterology 1995;109:2029-31.
6. Sandler RS, Everhart JE, Donwitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11.
7. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-41.
8. Ricci JF, Jhingran P, McLaughlin T, et al. Costs of care for irritable bowel syndrome in managed care. J Clin Outcomes Manag 2000;7:23-8.
9. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122-9.
10. Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001;134:860-8.
11. Thompson WG, Creed FH, Drossman DA. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992;5:75-91.
12. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38: 1569-80.
13. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig Dis Sci 1993;38:1581-9.
14. Yawn BP, Locke GR, III, Lydick E, et al. Diagnosis and care of irritable bowel syndrome in a community-based population. Am J Manag Care 2001;7:585-92.
15. Longstreth GF. Irritable bowel syndrome and chronic pelvic pain. Obstet Gynecol Surv 1994;49:505-7.
16. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000;87:1658-63.
17. Creed F. Life events and appendicectomy. Lancet 1981;1: 1381-5.
18. Levy RL, Whitehead WE, Feld AD. Do patients with IBS receive a diagnosis of IBS, abdominal pain, constipation or diarrhea? Am J Gastroenterol 2001;96(suppl):S320 (abstract).
19. Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553-9.
20. Talley NJ, Zinsmeister AR, Melton LJ, III. Irritable bowel syndrome in a community: Symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995;142:76-83.
21. Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000;95:974-80.
22. Hu TW, Rush AJ. Depressive disorders: Treatment patterns and costs of treatment in the private sector of the United States. Soc Psychiatry Psychiatr Epidemiol 1995;30:224-30.
23. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70.
24. Walen HR, Cronan PA, Bigatti SM. Factors associated with healthcare costs in women with fibromyalgia. Am J Manag Care 2001;7:SP39-SP47.
25. Lipton RB, Stewart WF, Von Korff M. Burden of migraine: Societal costs and therapeutic opportunities. Neurology 1997; 48:S4-S9.
26. Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia 1999;19:50-7.
27. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-62.
28. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998;47:446-52.
29. Fass R, Longstreth GF, Pimentel M, et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001;161:2081-8.
30. Knight K, Higuchi K, Wilson A. Diagnosis of irritable bowel syndrome in managed care: Missed opportunity? Am J Gastroenterol 2001;96(suppl):S272 (abstract).
31. Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: A case study of osteoarthritis from a managed care system perspective. Value Health 2001;4:329-34.